FASTRACK II

Trial Title:

TROG 15.03 Focal Ablative STereotactic RAdiosurgery for Cancers of the Kidney  - A Phase II Clinical Trial

Trial Acronym:  FASTRACK II

Protocol Number:

TROG 15.03

Trial Design:

Phase II, non-randomised study

ANZ Study Chairs:

A/Prof Shankar Siva

ANZ Coordinating Centre:

TROG Cancer Research

Trial Coordinator:

Rebecca Montgomery

Trial Email:

FASTRACKII@trog.com.au

Patient Population: Renal cell carcinoma (RCC) 
Intervention:  Radiotherapy;
  • Fraction schedule 1: 26Gy in 1 fraction, for tumours <4cm in size
  • Fraction schedule 2: 42Gy in 3 fractions, for tumours >4cm in size

Primary Outcome:

To estimate the efficacy of SABR for primary RCC

Secondary Outcomes:

  1. To estimate the tolerability of SABR for primary RCC
  2. To characterise overall survival
  3. To characterise cancer specific mortality after SABR
  4. To estimate the distant failure rate after SABR
  5. To describe renal function change after SABR

Status:

Open

Sites Recruiting:

NSW

  • Calvary Mater Newcastle

  • Royal North Shore Hospital

VIC

  • Peter MacCallum Cancer Centre

  • The Alfred (William Buckland Radiation Centre)

SA

  • Royal Adelaide Hospital

QLD

  • Princess Alexandra Hospital 

Further Information: Click here
© ANZUP 2017. All rights reserved.